Key result
De novo ICD implantation was associated with a high overall reoperation rate of 12.0% per patient-year and a 5-year mortality of 32.7%.
Why the study?
What are the long-term complication, reoperation, and survival rates following de novo implantable cardioverter-defibrillator (ICD) implantation?
Cohort (n=3,410)
Yes
What are the long-term complication, reoperation, and survival rates following de novo implantable cardioverter-defibrillator (ICD) implantation?
De novo ICD implantation is associated with substantial long-term complication and reoperation rates that increase with device complexity, highlighting the need for careful shared decision-making.
Reoperation rates rise with device complexity; leaves open optimal ICD selection strategies pending randomized trials.
OBJECTIVE: Implantable cardioverter-defibrillators (ICDs) reduce risk of death in select populations, but are also associated with harms. We aimed to characterise long-term complications and reoperation rate. METHODS: We assessed the rate, cumulative incidence and predictors of long-term reoperation and survival using a prospective, multicentre registry serving British Columbia in Canada, a universal single payer healthcare system with 4.5 million residents. 3410 patients (mean 63.3 years, 81.7% male) with new primary (n=1854) or secondary prevention (n=1556) ICD implant from 2003 to 2012 were followed for a median of 34 months (single chamber n=1069, dual chamber n=1905, biventricular n=436). Independent predictors of adverse outcomes were defined using Cox regression models. RESULTS: The overall reoperation rate was 12.0% per patient-year, and less for single vs dual vs biventricular ICDs (9.1% vs 12.5% vs 17.8% per patient-year, respectively). The Kaplan-Meier complication estimates (excluding generator end of life) at 1, 3 and 5 years were respectively: single chamber 10.2%, 16.2% and 21.6%; dual 11.7%, 19.1% and 27.4% and biventricular 15.9%, 22.2% and 24.7%. Cardiac resynchronisation therapy had the highest rate of early lead complications, but lower long-term need for upgrade. Device complexity, age and atrial fibrillation were key determinants of complications. Overall mortality at 1, 3 and 5 years was 5.4%, 17.4% and 32.7%, respectively. In younger patients, observed 5-year survival approached the expected survival in the general population (relative survival ratio=0.96 (0.90-0.98)). With increasing age, observed survival steadily declined relative to expected. CONCLUSIONS: In a prospective registry capturing all procedures, complication and reoperation rates following de novo ICD implantation were high. Shared decision making must carefully consider these factors.
No takes yet. Share an insight, caveat, or question.
Hawkins et al. (2017) conducted a cohort in New primary or secondary prevention ICD implant (n=3,410). Implantable cardioverter-defibrillator (ICD) vs. Single vs dual vs biventricular ICDs was evaluated on Overall reoperation rate. De novo ICD implantation was associated with a high overall reoperation rate of 12.0% per patient-year and a 5-year mortality of 32.7%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: